GlassScriptPhysician profile
Vivek T Das
NPI 1487684858
$2,525.82
in general payments reported to CMS, 2019-2025
39 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $445 · 2021: $429 · 2022: $276 · 2023: $193 · 2024: $258 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.46 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $401.93 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $138.15 | 2022 | |
| Tersera Therapeutics LLC | $113.32 | 2019-2024 | Prialt |
| Pfizer INC. | $108.84 | 2019-2025 | |
| Biodelivery Sciences International, INC. | $99.51 | 2020-2021 | |
| Abbvie INC. | $91.66 | 2022-2025 | Qulipta |
| Teva Pharmaceuticals USA, INC. | $72.47 | 2019-2021 | |
| Boston Scientific Corporation | $69.75 | 2019-2025 | General - Pain Management |
| Virtus Pharmaceuticals LLC | $55.41 | 2021-2025 | Levorphanol Tartrate |
| Daiichi Sankyo INC. | $50.98 | 2019 | |
| Allergan, INC. | $50.17 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $49.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.46 | 2019-2020 | |
| Redhill Biopharma INC. | $36.22 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.78 | 2023-2024 | Bridion |
| Glaxosmithkline, LLC. | $29.81 | 2024 | Arexvy, Trelegy Ellipta |
| Bioventus LLC | $27.86 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $27.10 | 2021-2022 | |
| Almatica Pharma LLC | $26.59 | 2021 | |
| Avanos Medical | $22.35 | 2019 | |
| Stimwave Technologies Incorporated | $19.73 | 2019 | |
| Electronic Waveform Lab, INC. | $16.62 | 2025 | |
| Protega Pharmaceutials INC | $14.82 | 2024 | Roxybond |
| Eagle Pharmaceuticals, INC. | $14.63 | 2023 | |
| Forte Bio-Pharma LLC | $14.57 | 2023 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $14.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.86 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.44 | 2024 | |
| Kaleo, INC. | $13.37 | 2019 | |
| Shionogi INC | $13.25 | 2019 | |
| Baudax Bio INC. | $13.17 | 2020 | |
| Mdd US Operations, LLC | $12.72 | 2020 | |
| Horizon Therapeutics Plc | $12.58 | 2022 | |
| Pacira Therapeutics, INC. | $12.39 | 2019 | |
| Si-Bone, INC. | $12.32 | 2019 | |
| Assertio Therapeutics, INC. | $11.95 | 2019 | |
| Orthogenrx INC. | $11.21 | 2020 | |
| Amgen INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.